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INTRODUCTION 
Liver cancer is a leading cause of cancer-related mortality worldwide and 
accounts for more than 800.000 deaths per year. Hepatocellular carcinoma 
(HCC) is a common cancer with high lethality, which is diagnosed most often at 
advanced stages when surgical or local treatment options are not possible. For 
the treatment of advanced HCC, sorafenib has been the only approved systemic 
treatment for nearly 10 years. Lately however, a number of additional 
compounds targeting tumour-specific signalling pathways, such as regorafenib, 
lenvatinib, and cabozantinib, and most recently, ramucirumab, provided positive 
results in phase-3 clinical trials. In addition, the approval of nivolumab as 
second-line treatment revealed the importance of the immune response in 
determining the development in HCC and set the stage for extensive clinical 
research with these agents. These new therapeutic options for HCC have 
significantly prolonged the life expectancy in patients with advanced-stage 
disease and collectively provided evidence that targeted therapy in different 
lines of treatment is a feasible strategy also for HCC. Nevertheless, a great 
individual variability in clinical benefits in response to these agents can be 
observed, and prognosis remains extremely poor in the majority of patients not 
responding to the treatments.  
By the two presented research projects, we aimed at assessing new therapeutic 
targets and possible therapeutic strategies for the treatment of HCC.  
In the first project, which was previously published in the form of an abstract 1, 
we explored the possibility of enhancing the therapeutic potential of sorafenib 
by its combination with the novel and clinically viable PI3K-Akt-Tor inhibitor 
copanlisib. To this regard, we found that copanlisib possesses potent anticancer 
activity as single agent and acts synergistically in combination with sorafenib in 
INTRODUCTION 
 
 
9 
 
 
human HCC, hereby representing a rational potential therapeutic option for 
advanced HCC.   
In the second project, which was also presented and published as an abstract 2, 
we investigated the role of olfactomedin 4 (OLFM4), a glycoprotein 
predominantly expressed in bone marrow and gastrointestinal tract, in the 
pathogenesis of HCC. By performing immunohistochemical staining in human 
HCC tissues and functional in vitro assays of Huh7 and HepG2 cell lines, we 
provided the first report on a possible role of this molecule in determining the 
development of HCC by showing that increased expression of OLFM4 is a 
common event in the pathogenesis of this tumor with independent prognostic 
significance. 
Our preclinical results from these two studies, which are presented in the form 
of the two different manuscripts about to be submitted or published, warrant 
further investigation of PI3K-Akt-Tor signalling as a mechanism of cancer 
development and chemoresistance during HCC treatment, as well as of the role 
played by OLFM4 in determining invasion and metastasis in this tumor.
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The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death 
in hepatocellular carcinoma (HCC) 
ABSTRACT 
Background: Sorafenib, a multikinase inhibitor targeting the Ras/Raf/MAPK 
and VEGF signaling pathways is an established treatment option for patients 
with advanced-stage hepatocellular carcinoma (HCC); however, despite its 
clinical benefit, chemoresistance and disease progression eventually occur 
almost invariably during treatment. Activation of the PI3K/AKT pathway plays 
a role in the pathogenesis of HCC and may contribute to determine resistance to 
sorafenib. We thus evaluated in vitro the effects of the combination of sorafenib 
and copanlisib, a PI3K inhibitor recently approved for clinical use. 
Methods: The effects of copanlisib alone and in combination with sorafenib 
were assessed in several HCC cell lines by proliferation and colony formation 
assays, FACS analyses, and western blot. In addition, sorafenib-resistant cell 
clones were used. 
Results: Copanlisib strongly reduced cell viability and colony formation in 
different native and sorafenib-resistant HCC cell lines by affecting cyclin 
D1/CDK4/6 signaling and causing cell cycle arrest. Elevation of p-AKT was 
observed upon incubation with sorafenib and was consistently found in 6 
different unstimulated sorafenib-resistant cell clones. Copanlisib counteracted 
sorafenib-induced phosphorylation of p-AKT and synergistically potentiated its 
antineoplastic effect. 
Conclusion: Copanlisib shows potent anticancer activity as single-agent and 
acts synergistically in combination with sorafenib in human HCC. Combination 
of sorafenib with copanlisib represents a rational potential therapeutic option for 
advanced HCC.  
COPANLISIB ZUSAMMENFASSUNG 
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Der PI3K-Inhibitor Copanlisib synergisiert mit Sorafenib, um den Zelltod 
bei einem hepatozellulären Karzinom (HCC) zu induzieren 
ZUSAMMENFASSUNG 
Hintergrund: Die Therapie mit Sorafenib, einem gegen die Ras/Raf/MAPK- 
und VEGF-Signalwege gerichteter Multikinase-Inhibitor, ist eine etablierte 
Behandlungsoption für Patienten mit fortgeschrittenem hepatozellulärem 
Karzinom (HCC). Trotz des klinischen Nutzens treten unter der Behandlung fast 
immer eine Chemoresistenz und ein Fortschreiten der Krankheit auf. Die 
Aktivierung des PI3K/AKT-Signalwegs spielt eine Rolle in der Pathogenese des 
HCCs und kann zur Entstehung einer Resistenz gegen Sorafenib beitragen. 
Daher haben wir die Wirkung von Sorafenib in Kombination mit Copanlisib, 
einem kürzlich für die klinische Anwendung zugelassenen PI3K-Inhibitor, in 
vitro untersucht. 
Methoden: Die Effekte von Copanlisib allein und in Kombination mit Sorafenib 
wurden in mehreren HCC-Zelllinien mittels Proliferations- und 
Koloniebildungsassays, FACS-Analysen und Western Blot untersucht. 
Zusätzlich wurden Sorafenib-resistente Zellklone verwendet. 
Ergebnisse: Copanlisib reduzierte die Zelllebensfähigkeit und Koloniebildung 
in verschiedenen nativen und Sorafenib-resistenten HCC-Zelllinien stark, indem 
es den Cyclin D1/CDK4/6 Signalweg beeinflusste und einen Zellzyklusstillstand 
verursachte. Eine Erhöhung von p-AKT wurde nach Behandlung mit Sorafenib 
beobachtet und konnte in sechs verschiedenen nicht stimulierten Sorafenib-
resistenten Zellklonen übereinstimmend gefunden werden. Copanlisib wirkt der 
Sorafenib-induzierten Phosphorylierung von p-AKT entgegen und potenziert 
synergistisch dessen antineoplastischen Effekt. 
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Schlussfolgerung: Copanlisib zeigt eine starke antitumoröse Akitvität als 
Einzelwirkstoff und wirkt in Kombination mit Sorafenib im humanen HCC 
Zelllinien synergistisch. Die Kombination von Sorafenib mit Copanlisib stellt 
eine rationale mögliche therapeutische Option für das fortgeschrittene HCC dar.
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the second cancer-related cause of death 
worldwide accounting for about 800,000 deaths every year and its incidence is 
expected to progressively increase in the future 3-5. The improvement of local 
and locoregional therapies, the definition of selection criteria for liver 
transplantation, and the implementation of screening programs for early 
diagnosis have contributed to the amelioration of survival of HCC patients 6. In 
addition, the advent of sorafenib 7 and the recent positive results of clinical trials 
investigating new compounds such as regorafenib 8, lenvatinib 9, nivolumab 10 
and, most recently, cabozantinib 11, shows that the sequential employment of 
compounds targeting different signaling pathways is a therapeutic strategy 
applicable to the treatment of HCC,  promising to further ameliorate the life 
expectancy of patients with advanced stage tumors. Future treatment schemas 
will thus likely consist of the combination of different kinase inhibitors 
simultaneously targeting different intracellular signaling pathways to overcome 
chemoresistance to single treatment regimens and/or their combination with 
immune checkpoint inhibitors 12. 
Sorafenib is a multikinase inhibitor which influences a number of different 
signalling pathways, including the Ras/Raf/MAPK pathway, VEGF- and PDGF-
signalling, hereby affecting different aspects of cell biology including 
proliferation, apoptosis and angiogenesis 13. Unfortunately, due to both the 
molecular heterogeneity of HCC and the broad spectrum of kinase inhibition 
peculiar of sorafenib, in spite of substantial efforts, no reliable predictors of 
response to this drug could be found yet, and the precise mechanism of action of 
sorafenib remains to be precisely elucidated. Nevertheless, the observation that 
recurrent molecular changes occur in consequence of sorafenib treatment 
(including increase of c-MET 14 and the activation of the phosphatidylinositol-3-
COPANLISIB INTRODUCTION 
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kinase (PI3K)-serine/threonine kinase (AKT)-mammalian target of rapamycin 
(mTOR) signalling pathway 15,16) indicates that concomitant inhibition of these 
signalling pathways can be exploited to overcome resistance to sorafenib. The 
compensatory activation of these signalling pathways is in keep with the 
significance of c-MET and PI3K-Akt-Tor signalling in the pathogenesis of HCC 
recently highlighted by extensive genetic investigation of this tumor 17,18. 
Copanlisib (BAY 80-6946) is a novel PI3K inhibitor which demonstrated 
effectiveness in various tumour entities in preclinical models 19-22 and is 
currently undergoing extensive clinical investigation. Most recently, copanlisib 
was granted accelerated approval for therapy of follicular lymphoma recurrence. 
Here, we aimed at assessing the potential antineoplastic effect of copanlisib in 
HCC cell lines and its potential as a sensitizer to the antineoplastic effect of 
sorafenib in a preclinical model.
COPANLISIB MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Cell lines and reagents 
Huh7, HepG2, PLCPRF5, Chang cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) and Hep3B cells were cultured in Minimum Essential 
Medium Eagle (MEM) (Sigma Aldrich, Munich, Germany) with 10% fetal 
bovine serum (Biochrom GmbH, Berlin, Germany), 1% penicillin-streptomycin 
(Sigma Aldrich, Munich, Germany). Cells were maintained in 5% CO2 at 37 ℃. 
Copanlisib (BAY 80-6946, Selleckchem, Munich, Germany) and sorafenib 
(Selleckchem, Munich, Germany) were stored at −20°C and dissolved in 100% 
dimethyl sulfoxide (DMSO) at a stock concentration of 5 mMol and 43 mMol, 
respectively. Two sorafenib resistant sublines were established from Huh7 and 
HepG2 cells, termed sorafenib-resistant Huh7 (Huh7-SR) and sorafenib-
resistant-HepG2 (HepG2-SR), by incubation with increasing doses of sorafenib 
(2 µM, 4 µM, and 6 µM) for at least eight months. Authentication of cell lines 
was conducted by Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures. 
Cell proliferation assays 
1,000 to 1,500 cells were seeded in 96-well plates, cultured overnight, and then 
incubated in the presence of various concentrations of copanlisib and/or 
sorafenib. After 6 days, cells were washed with PBS and underwent osmotic 
lysis in 100 µl ddH2O for 45 minutes at 37 ℃. 0.2% Sybr green (Lonza, 
Rockland, ME, USA) was added to each well, fluorescence was measured 
(GloMax-Multi+Detection System with Instinct Software, Promega, USA) and 
proliferation index was calculated as a ratio to untreated samples. Three 
independent experiments were performed per agent, with each data point 
reflecting triplicate wells. Error bars represented standard deviation of the mean 
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(SD) from three experiments. Data were analysed by using CompuSyn (Biosoft, 
Ferhuson, MO, USA) to calculate the IC50 to determine the IC50 of the assessed 
drugs. The same software was used was used to draw isobolograms and 
calculate the Chou-Talalay combination index (CI), an established method to 
calculate drug-interaction as previously described 23. Combination index values 
of <1, 1, and >1 indicated synergistic, additive, and antagonistic effects, 
respectively.  
Colony formation assay 
5,000 cells were seeded in 6-wells plates. After overnight incubation, cells were 
exposed to copanlisib for 48 hours. Fresh medium was replaced regularly and 
the plates were maintained at 37 ℃ for three weeks. Colonies were counted after 
fixation in 9% paraformaldehyde and staining with crystal violet for 30 minutes 
(Sigma, St. Louis, MO, USA). 
Apoptosis and cell cycle assays 
8.0×104 to 1.5×105 cells were seeded in 6-well plates. After overnight incubation 
and incubation with the respective agents, propidium iodide (PI) staining and 
fluorescence-activated cell sorting (FACS - Accuri C6 flow cytometer, BD 
Biosciences San Jose, CA USA) were performed to assess the fraction of 
apoptotic cells as determined by the sub-diploid DNA content (Sub-G1). In 
addition, apoptosis was assessed by Hoechst staining and fluorescence 
microscopy (Zeiss, Jena, Germany). 
Western blot 
Equal amount of proteins in each sample was loaded on 10/12% SDS-PAGE 
gels and separated for 25 minutes at 80 V and for 80 minutes at 120 V, then 
transferred onto PVDF membranes (EMD Millipore Corporation, Billerica, MA, 
COPANLISIB MATERIALS AND METHODS 
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USA). After blocking for 1 hour in TBST (tris-buffered saline with Tween-20) 
containing 5% milk or 5% bovine serum albumin, membranes were incubated 
overnight at 4℃ with the following primary antibodies: p-AKT (S473), AKT, β-
actin, Caspase-3, Caspase-8, Caspase-9, Cyclin B1, Cyclin D1, p53, p21, CDK4, 
CDK6, Bad, Bax, Bak, Bcl-2, Bcl-xL (Cell Signaling Technology, USA) and 
Bid (FL-195; Santa Cruz, Germany). Subsequently, the membrane was probed 
with horseradish-peroxidase conjugated secondary anti-rabbit or -mouse IgG 
antibodies (GE Healthcare UK Limited) for 2 hours at room temperature at 
concentrations of 1:10,000. The bands were visualized by SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific, Schwerte, Germany) and 
photographed with an image acquisition system (ECL ChemoCam Imager, Intas 
GmbH, Germany).  
Statistical analysis 
Data were analysed by SPSS version 22.0 (SPSS Inc, IL USA). Results were 
shown as mean ± standard deviation (SD) of at least three independent 
experiments and statistical difference were assessed by Student’s t-test and one-
way analysis of variance (ANOVA) test followed by LSD method. Statistical 
significance was defined by P values < 0.05; ≠, P < 0.05; Ο, P < 0.01; *, P < 
0.001. The combination index was determined as described above 23.
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RESULTS 
Copanlisib exerts a potent anti-proliferative effect as single agent in HCC 
cells.  
The effect of copanlisib on cell viability was assessed in 5 HCC cell lines 
exhibiting different baseline levels of p-AKT expression (Fig. 1A). As shown in 
Fig. 1B, the effect of copanlisib on p-AKT was readily observable after one-
hour incubation at the concentration of 100 nM. Copanlisib dose-dependently 
inhibited cell growth in vitro in clinical concentration-range regardless of 
baseline levels of p-AKT, hereby showing higher potency in Huh7 and HepG2 
(IC50=47.9 and 31.6 nM, respectively) vs Hep3B, PLCPRF5 or Chang cells 
(IC50=72.4, 283 nM, and IC50=442nM respectively; Fig. 1C). These results were 
clearly confirmed by clonogenicity assays, showing a dose-dependent reduction 
in number and size of colonies in Huh7 and HepG2 cells upon incubation with 
copanlisib (Fig. 1D-E). 
 
Copanlisib causes G1 cell cycle arrest and downregulation of cyclin B1 and 
D1.  
Since copanlisib was previously shown to cause apoptosis by inhibiting the 
antiapoptotic protein Bcl-xL in breast cancer cells 24, apoptosis and cell cycle 
were assessed to determine their respective contribution to its antineoplastic 
effect in HCC cells. Surprisingly, we found only little or quantitatively 
negligible apoptosis, as shown by the time-kinetic of sub-G1 events at different 
time points until 72 hours after addition of copanlisib at the concentrations of 
100 and 200 nM (Fig. 2A-C). This was confirmed by the absence of typical 
microscopic features of apoptosis, like chromatin condensation and nuclear 
fragmentation at Hoechst staining (Fig. 2D). Instead, incubation with copanlisib 
COPANLISIB RESULTS 
 
 
19 
 
 
for up to 72 hours caused a clear, dose- and time- dependent G1 cell cycle arrest, 
along with a corresponding decrease of the S and G2/M phases of cell cycle 
(Fig. 2E-G). Correspondingly, as key modulators of cell death and cell cycle 
were assessed, no caspase cleavage could be detected (Fig. 3). Instead, cell cycle 
arrest was accompanied by a significant reduction of cyclin B1 and cyclin D1 24 
to 72 hours after addition of copanlisib. Concomitantly, an increase of both p53 
and p21 and a decrease of CDK4 and CDK6 were observed (Fig. 3). These data 
point to the fact that copanlisib used as single agent affects the viability of HCC 
cells mainly by inducing cell cycle arrest by downregulating CDK4/6 and cyclin 
D1, which are downstream targets of AKT, but only marginally effects 
apoptosis. 
 
Copanlisib synergizes with sorafenib by counteracting sorafenib-induced 
activation of AKT.  
Since sorafenib-induced increase of AKT phosphorylation is thought to 
represent a mechanism of chemoresistance counteracting the antineoplastic 
effect of sorafenib 16,25,26, we assessed the effect of combined sorafenib and 
copanlisib in HCC cells. As expected, sorafenib strongly diminished cell 
viability alone hereby causing increased expression and cleavage of procaspase 
3 and 9 (Fig. 4). In the same time, however, incubation with sorafenib induced 
increase of p-AKT, cyclin B1 and cyclin D1. However, this effect could be 
reversed by co-incubation with copanlisib. In addition, co-administration of 
sorafenib and copanlisib increased caspase cleavage. The antineoplastic 
interaction between sorafenib and copanlisib was confirmed by CI and 
isobologram blots showing that copanlisib and sorafenib synergize to determine 
the loss of cell viability in Huh7 and HepG2 cells (Fig. 4B-E). Altogether these 
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data suggest that sorafenib-mediated activation of AKT and cyclin D1 might 
represent a mechanism of resistance limiting the antineoplastic potential of 
sorafenib. 
To confirm these findings, we established several cell lines with acquired 
resistance to sorafenib by long-term exposure to increasing concentrations of 
this agent. As expected, such Huh7- and HepG2-derived cells lines were less 
sensitive to sorafenib in comparison to their wild-type counterpart (Fig. 5A-B). 
In addition, they exhibited increased levels of phosphorylated AKT, of cyclin 
D1, of CDK4 and CDK6 (Fig. 5C), an effect which could be counteracted by 
copanlisib (Fig. 5D). Correspondingly, as shown by viability experiments, 
copanlisib restored sorafenib sensitivity in sorafenib-resistant cells (Fig. 5E-F). 
Taken together, these results indicate that increase of AKT is not only triggered 
in response to sorafenib but also represents a mechanism of acquired resistance 
developing after long-term exposure to this agent. AKT inhibition by copanlisib 
counteracts this mechanism of resistance hereby sensitizing cancer cells to 
sorafenib.  
 
Co-treatment with copanlisib and sorafenib increases apoptosis by a 
caspase-dependent mechanism.  
To investigate the mechanisms underlying the synergistic interaction between 
copanlisib and sorafenib in Huh7 and HepG2 cells, we examined the effect of 
their combination in determining cell cycle and apoptosis. In agreement with the 
observed increase in caspase cleavage caused by co-stimulation with both agents 
(Fig. 4A), a synergistic increase of apoptosis (Fig. 6A-C) and an additive 
increase of cell cycle arrest were observed (Fig. 7A-C). At molecular level, 
western blot analysis showed that the combined substances cause an increase of 
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the proapoptotic proteins bad, bid, bax, and bak and a decrease of the 
antiapoptotic molecules Bcl-2 and Bcl-xL (Fig. 8A). 
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DISCUSSION 
Derangement of the PI3K signaling pathway is one of the most common events 
in cancer development 27,28 and is thought to play a role in the development of 
approximately 50% of HCC 17. Sorafenib, a standard first-line treatment option 
for HCC, is known to possess a broad spectrum of kinase inhibition, but has 
little effect on the activity of the PI3K-Akt-Tor signaling, a pathway which, as 
recently proposed 29,30 might represent a mechanism of acquired resistance to 
this agent.  
Copanlisib is a newly developed pan-PI3K inhibitor which has most recently 
been approved for the treatment of relapsed follicular lymphoma 31 and is 
undergoing clinical experimentation for the treatment of indolent or aggressive 
NHL 32. In addition, copanlisib is being assessed for the treatment of solid 
tumors in preclinical studies 19,22,24 and in early-phase clinical trials showing 
signs of effectiveness and acceptable toxicity 33,34. The availability of this agent 
for clinical use represented the rationale for assessing its combined effect with 
sorafenib for treatment of HCC. 
In our model, copanlisib showed remarkable antiproliferative properties in 
different HCC cell lines independently of their basal expression of AKT. 
Previous investigation in breast cancer cells had shown that copanlisib causes 
apoptosis by down-regulating the expression of the antiapoptotic protein Bcl-xL 
24. In contrast, our findings show that copanlisib suppresses tumor growth in 
HCC cells mainly by triggering a G1 cell cycle arrest by inhibiting the cyclin 
D1/CDK4/CDK6 axis (Fig. 8B), without causing apoptosis (Fig. 3). Cyclin D1, 
CDK4 and CDK6 are regulated by the PI3K-Akt-Tor signalling pathway and 
control the progression from the G1 to the G2 phase of cell cycle by 
phosphorylating the tumour suppressor Rb , which in turn causes the activation 
COPANLISIB DISCUSSION 
 
 
23 
 
 
of the transcription factor E2F 35. Extensive efforts to characterize the 
mutational landscape of HCC by exome sequencing recently conducted by the 
group of Zuckmann-Rossi and colleagues has revealed that amplification of 
cyclin D1 is one of the most frequent events during HCC development and is 
independently associated with a poor prognosis 17. The frequent activation of the 
PI3K-Akt-Tor signalling and amplification of cyclin D1 in HCC corroborate the 
rationale for assessing copanlisib as a treatment option in patients with advanced 
HCC. 
In addition to its antiproliferative properties as single agent, copanlisib also 
synergistically potentiates the effect of sorafenib, which is consistent with the 
notion that the activation of PI3K serves as mechanism of escape from the 
inhibition of Ras-Raf-MAPK signalling. We correspondingly found that p-AKT 
as well as cyclin-B1, -D1 and CDK4/6 were increased by sorafenib, an effect 
which could be completely abrogated by copanlisib. Our observations are in 
accordance with previous studies showing that interruption of PI3K/AKT 
signaling sensitizes tumor cells to sorafenib-induced apoptosis 16 and with the 
fact that we consistently found high basal levels of p-AKT, CDK4/6 and cyclin 
D1 in cell lines with acquired resistance to sorafenib.  
Interestingly, we observed that the mechanisms underlying the effects of the 
combined agents were different those observed with copanlisib alone. 
Copanlisib had little effect on apoptosis, which was instead remarkably 
increased by the combination of both agents. This proapoptotic effect was 
caused by the activation of the intrinsic signaling pathway, in particular owing 
to the profound down-regulation of the antiapoptotic molecules Bcl-2 and Bcl-
xL, an effect which was previously suggested as mechanism of action of 
copanlisib in breast cancer cells 24.  
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While our results suggest the possibility that copanlisib could be used as 
treatment option for patients with advanced HCC alone or in combination with 
sorafenib, copanlisib might also be used in combination with other anticancer 
agents, comprising immune checkpoint inhibitors. The association of immune 
checkpoint inhibitors with kinase inhibitors seems to represent a promising 
therapeutic approach, as exemplified by a recent early-stage trial with combined 
lenvatinib and pembrolizumab 36. Since clinical evidence was provided on the 
efficacy of combined mTOR-inhibitors and PD-1/PD-L1 blocking agents in 
HCC and metastatic renal cell carcinoma 37,38, copanlisib could be used in 
combination with immune checkpoint inhibitors to potentiate the effect of these 
agents. 
Conclusion 
In summary, we highlight the role of PI3K-Akt-Tor signalling activation in 
inducing resistance to sorafenib, and shed light on the mechanism of action 
underlying the antineoplastic effects of copanlisib and its synergistic interaction 
with sorafenib. We suggest that copanlisib is considered as a potential treatment 
option for HCC alone or in combination with sorafenib.
COPANLISIB FIGURES 
 
 
25 
 
 
FIGURES 
 
Fig. 1. Copanlisib affects cell viability and colony forming capability. A. Baseline levels 
of p-AKT expression in the indicated cell lines. B. Effect of copanlisib (copa) at the 
concentration of 100 nM on p-AKT. C. Changes in cell viability expressed as ratio to control-
treated cells at different concentrations of copanlisib. D. Representative pictures of colony-
formation of Huh7 and HepG2 cells and (E) colony count, after incubation with the indicated 
concentrations. Results are representative of three independent experiments. Error bars 
represent mean ± standard deviation (SD). 
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Fig. 2. Copanlisib causes a G1 cell cycle arrest. Sub-G1 events upon incubation with 
copanlisib at the concentrations of 100 and 200 nM in Huh7 (A) and HepG2 (B) cells 
showing marginal apoptosis; typical FACS pattern of sub-G1 cell fraction (C) and Hoechst 
staining (D) in these cell lines. Cell cycle analysis after incubation with copanlisib (copa) at 
the indicated concentrations and time points in Huh7 (E) and HepG2 (F) cells and respective 
representative features at FACS analysis (G). Reproducible results were obtained in at least 
three independent experiments. Error bars represent mean ± SD. ≠: P < 0.05; Ο: P < 0.01; *: 
P < 0.001, by independent sample t-test vs. untreated controls. In these experiments, to rule 
out the possibility that the observed lack of apoptosis could be due to diminishing 
effectiveness of copanlisib during incubation, fresh medium containing copanlisib at the 
appropriate concentrations was replaced every day. 
 
 
Fig. 3. Copanlisib triggers G1 cell cycle arrest by down-regulating cyclin B1 and D1. 
Immunoblot analyses of different regulators of apoptosis and cell cycle after incubation with 
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copanlisib (copa) at the concentration of 100 nM at the indicated time points. Three 
independent repeats.  
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Fig. 4. Copanlisib synergizes with sorafenib to determine loss of cell viability by 
counteracting sorafenib-induced PI3K/AKT activation. A. Western Blot analysis of Huh7 
and HepG2 after incubation with copanlisib and/or sorafenib at the indicated concentrations. 
B. C. Synergistic interaction between sorafenib and copanlisib in Huh7 (B) and HepG2 cells 
(C) as determined by cell viability. CI values of <1, 1, and >1 indicate synergistic, additive, 
and antagonistic effects, respectively (Copa: copanlisib; Sora: sorafenib; Combi: combination 
of both substances). D. Dose-effect relationship of copanlisib, sorafenib, and their 
combination (constant ratio of 1: 100) on growth inhibition of Huh7 cells (left panel). The 
combination index (CI) values and fraction affected (Fa) for each dose were used to generate 
the Fa-CI plot (middle panel) and isobologram blots (right panel). Panels of figure E represent 
for HepG2 the same information provided Huh7 cells. For viability assays cells were 
incubated with the indicated concentrations of copanlisib, sorafenib and their combination for 
six days. All in vitro assays were carried out on three independent experiments. Error bars 
represent mean ± SD. ≠, P < 0.05; Ο, P < 0.01; *, P < 0.001, by independent sample t-test 
compared with untreated control, respectively. 
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Fig. 5. Copanlisib restores the sensitivity of sorafenib-resistant Huh7 and HepG2 cell 
lines to sorafenib. A. B. Viability assay after incubation with sorafenib in wild type (WT) 
Huh7 and HepG2 cells and in cell lines which acquired resistance to sorafenib by long-term 
exposure at the respective concentrations of 2 µM (Rsora 2), 4 µM (Rsora 4) and 6 µM (Rsora 
6). C. Western blot of p-AKT and AKT in unstimulated Huh7 and HepG2 (WT) and in the 
indicated sorafenib-resistant cell lines. D. Western blot of p-AKT in sorafenib-resistant Huh7 
and HepG2 cells after incubation to copanlisib for 72 hours. E. F. Cell viability assays 
showing the effect of combined administration of copanlisib and sorafenib in the indicated 
sorafenib-resistant Huh7 (E) or HepG2 (F) cells. Error bars represent mean ± SD of three 
independent repeats. ≠, P < 0.05; Ο, P < 0.01; *, P < 0.001. 
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Fig. 6. Copanlisib sensitizes HCC cells to sorafenib by increasing susceptibility to 
apoptosis. A. Sub-G1 events and typical FACS patterns (B) after incubation with copanlisib 
with or without the addition of increasing concentrations of sorafenib in Huh7 and HepG2 cell 
lines. CI values of <1, 1, and >1 indicated synergistic, additive, and antagonistic effects, 
respectively. C. Combination index (CI) plot of sub-G1 events showing a synergistic 
interaction of sorafenib and copanlisib in determining apoptosis. Error bars represent mean ± 
SD of three independent repeats. ≠, P < 0.05; Ο, P < 0.01; *, P < 0.001, by independent 
sample t-test (Copa, copanlisib. Sora, sorafenib). 
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Fig. 7. Copanlisib sensitizes HCC cells to sorafenib by causing cell cycle arrest. A. Cell 
cycle analysis and typical FACS patterns (B) of cells incubated with copanlisib and sorafenib 
at the indicated concentrations and time points. C. Time cause of G1-phase. Error bars 
represent mean ± SD of three independent repeats. ≠, P < 0.05; Ο, P < 0.01; *, P < 0.001, by 
independent sample t-test (Copa, copanlisib. Sora, sorafenib). 
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Fig. 8. Effects of copanlisib and sorafenib on different intracellular signaling pathways 
in HCC cells. A. Western blot of critical regulators of apoptosis after stimulation with 
copanslisib and/or sorafenib for 72 hours. Data are representative of three independent repeats 
(Copa, copanlisib. Sora, sorafenib). B. Schematic diagram describing the hypothesized effect 
of copanlisib, sorafenib and their interaction on cell cycle and apoptosis. 
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Prognostic significance and functional relevance of olfactomedin 4 
(OLFM4) in the development of hepatocellular carcinoma 
ABSTRACT 
Background: Olfactomedin 4 (OLFM4) is a secreted glycoprotein 
predominantly expressed in bone marrow and gastrointestinal tract. Aberrant 
expression of OLFM4 in human cancers has been reported, but its biological 
function and significance remain poorly understood in hepatocellular carcinoma 
(HCC). The purpose of this study is to examine the expression of OLFM4 and 
its prognostic significance in patients with HCC.   
Methods: Immunohistochemical staining to assess expression and cellular 
distribution of OLFM4 was performed by using a tissue microarray comprising 
HCC tissues and matched non-tumour tissues from 157 HCC patients. 
Clinicopathologic characteristics and survival were analysed in 95 patients who 
underwent partial hepatectomy. The findings were validated in vitro by western 
blot and functional studies using siRNA directed against OLFM4 to assess its 
effect on cell motility and proliferation. 
Results: The fraction of HCC samples exhibiting positive OLFM4 staining in 
both cytoplasm and membrane was higher in comparison to that observed in 
hepatocytes from matched non-tumour tissue (61% vs. 39%). Cytoplasmatic 
staining for OLFM4 was associated with poorer survival (P = 0.008), vascular 
invasion (P = 0.048) and MMP-7 expression (P = 0.002). Multivariate analysis 
confirmed that cytoplasmatic staining of OLFM4 was associated with poorer 5-
year survival {58.3% vs. 17.3%; HR: 2.135 [95% confidence interval (CI), 
1,135 – 4.015]; P = 0.019}. 
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Conclusion: To our best knowledge, we provide here for the first time evidence 
on OLFM4 as a marker of prognosis in HCC and identify its role on cell 
invasion and metastasis formation 2.
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Prognostische Bedeutung und funktionelle Relevanz von Olfaktomedin 4 
(OLFM4) in der Entwicklung des hepatozellulären Karzinoms 
ZUSAMMENFASSUNG 
Hintergrund: Olfaktomedin 4 (OLFM4) ist ein sekretiertes Glykoprotein, das 
vorwiegend im Knochenmark und im Gastrointestinaltrakt exprimiert wird. 
Wohingehend eine anomale Expression von OLFM4 bei humanen 
Krebserkrankungen bereits berichtet wurde, ist diese beim hepatozellulären 
Karzinom (HCC) jedoch noch wenig verstanden. Ziel dieser Studie ist es, die 
Expression von OLFM4 und seine prognostische Bedeutung bei Patienten mit 
HCC zu untersuchen. 
Methoden: Die immunhistochemische Färbung zur Beurteilung der Expression 
und der Zellverteilung von OLFM4 wurde unter Verwendung eines 
Gewebemikroarrays durchgeführt, das HCC-Gewebe und passende Nicht-
Tumorgewebe von 157 HCC-Patienten umfasst. Die klinisch-pathologischen 
Merkmale und das Überleben wurden bei 95 Patienten analysiert, die sich einer 
partiellen Hepatektomie unterzogen hatten. Die Ergebnisse wurden in vitro 
durch Western Blot und Funktionsstudien unter Verwendung von gegen OLFM4 
gerichteter siRNA validiert, um dessen Effekte auf die Zellmotilität und -
proliferation zu bewerten. 
Ergebnisse: Die Fraktion der HCC-Proben, die eine positive OLFM4-Färbung 
sowohl im Zytoplasma als auch an der Membran zeigten, war höher im 
Vergleich zu dervon Hepatozyten aus übereinstimmendem Nichttumorgewebe 
(61% vs. 39%). Die zytoplasmatische Färbung von OLFM4 war mit einem 
schlechteren Überleben (P = 0,008), einer Gefäßinvasion (P = 0,048) und der 
MMP-7-Expression (P = 0,002) verbunden. Eine multivariate Analyse 
bestätigte, dass die zytoplasmatische Färbung von OLFM4 mit einem 
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schlechteren 5-Jahres-Überleben verbunden war (58,3% vs. 17,3%; HR: 2,135 
[95% -Konfidenzintervall (CI), 1,135 - 4,015]; P = 0,019}. 
Schlussfolgerung: Nach unserem besten Wissen konnten wir hier erstmals 
OLFM4 als einen Marker für die Prognose des HCCs nachweisen und seine 
Rolle für die Zellinvasion und Metastasierungsbildung aufzeigen.
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INTRODUCTON 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
death worldwide with approximately 800,000 people dying each year 5,39. In 
very early disease stages HCC can be treated in curative intention via surgery or 
local ablative procedures. Unfortunately, most patients are diagnosed in 
advanced stages or progress under therapy to stages 40. The identification of new 
markers that are functionally involved in tumour development and progression 
may contribute to identify patients who are at high risk of tumour progression 
and could benefit from more intensive treatment or surveillance under therapy.  
Olfactomedin 4 (OLFM4, also known as GW112 or hGC-1), is a secreted 
glycoprotein found in different tissues, comprising hematopoietic myeloid cells, 
the gastrointestinal tract, and prostate 41. Overexpression of OLFM4 has been 
found in solid neoplasm such as gastric 42, colorectal 43, pancreatic 44, lung, and 
breast cancer 45 as well as in leukemia cells 46. Furthermore, an association of 
OLFM4 and liver metastases of colorectal cancer was described earlier 47. 
Increased OLFM4 mRNA levels has been shown in gastric, colon, pancreatic, 
breast and lung cancers at initial stages 45,48,49; in addition, serum OLFM4 levels 
were significantly higher in patients with gastric cancer than in non-tumor 
patients 50. It has thus been suggested that OLFM4 is a marker of gastrointestinal 
cancer development and that its expression could be used as biomarker to 
identify patients who are at greater risk for disease progression 51,52. Specifically, 
functional studies have shown that OLFM4 might play a role in determining cell 
motility and metastasis formation, since high expression levels of OLFM4 have 
been found to decrease adhesion and increase migration in colon cancer cells 52. 
OLFM4 was also shown to attenuate apoptosis via inhibiting the intrinsic 
apoptotic pathway by a blockade of caspase 3 and caspase 9 in gastric and 
prostate cancer cells 53,54. Genetic alterations of OLFM4 have been found to 
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correlate with tumour differentiation, metastasis formation and prognosis in 
numerous cancers, suggesting that OLFM4 could be used as an early marker of 
tumor development 55. 
In summary, although cumulative evidence points to a role of OLFM4 in cancer 
development, the relevance of this molecule in the pathogenesis of HCC has not 
yet been investigated. To address this issue we thus examined the expression 
and cellular distribution of OLFM4 in HCC tissues and matched non-tumour 
tissues, and investigated the potential relationship of OLFM4 staining with 
patient clinicopathologic features and survival. 
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MATERIALS AND METHODS 
Patients and pathologic material  
Patients with HCC who underwent liver transplantation or partial liver resection 
at the University Hospital, LMU Munich during the time-period 1985 and 2015 
were considered for the study. To avoid a potential bias related to the 
exceptionally favourable prognosis of patients undergoing liver transplantation, 
patients who received liver transplantations were not considered for analysis of 
survival. Data on survival were obtained from the Munich Cancer Registry 
(MCR; http://www.tumorregister-muenchen.de). Archival pathological material 
from the Institute of Pathology of the University of Munich. The characteristics 
of the tissue microarray containing tumour samples and matched tumor tissues 
has been previously described 56. 
Immunohistochemical staining  
Sections (5 μm) of tissue microarray blocks were used for immunohistochemical 
staining. Anti-OLFM4 polyclonal rabbit antibody (BIOZOL GmbH, Germany), 
anti-MMP-7 monoclonal mouse antibody (Merck KgaA, Germany), and anti-E-
cadherin monoclonal mouse antibody (Cell Signaling Technology, USA) were 
applied as primary antibodies. Samples have been processed for antigen retrieval 
as previously described 57. Vectastain ABC Elite Universal (Vector Laboratories 
Inc., USA) kit was used for immunohistochemical staining; AEC (Zytomed 
Systems, Germany) was used as a chromogen. Positive staining for OLFM4 was 
categorized according to its cellular distribution and independently of total 
staining intensity according to the following cathegories: cytoplasmatic staining; 
staining on cell membranes only; positive staining signals in both cytoplasm and 
cell membrane. In addition, we conducted a semiquantitative analyses by 
categorizing samples according to the percentage of cells exhibiting staining for 
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OLFM4 as follows: score 0: no staining; score 1: staining in < 30% of cells; 2: 
staining in 30% to 70% of cells; 3: staining in > 70% cells. Concerning OLFM4 
cytoplasmic staining: score 0, negative staining; score 1, weak staining; score 2, 
strong staining.  
Histologic assessment of tumours and surrounding non-tumour tissues  
Tumor grading according to the WHO criteria 58, presence of vascular invasion, 
number and size of tumor lesions (as defined by macroscopic inspection of 
surgical specimens) were analysed as tumor-associated pathological variables. 
Matched tissues not containing tumor material were analysed features related to 
the underlying liver disease and comprised the presence and quantification of 
fibrosis/cirrhosis, of portal inflammation, piecemeal necrosis, and steatosis. 
Histologic evaluation performed on haematoxylin and eosin-stained slides and 
evaluated by a senior pathologist and two of the authors who had not prior 
knowledge of prognostic data. The Ishak score was used to evaluate liver 
fibrosis, portal inflammation, and piecemeal necrosis 59. The nonalcoholic fatty 
liver disease activity score and staging system was used for assessment of 
steatosis and lobular infiltration 60. 
Cell culture 
Huh7 and PLCPRF5 cells (ATCC, USA) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma Aldrich, Germany) with 10% Fetal Bovine 
Serum (FBS; Biochrom GmbH, Germany) and 1% Penicillin-Streptomycin 
(Sigma Aldrich, Germany). Cells were maintained in 5% CO2 at 37°C. 
Authentication of cell lines was conducted by Leibniz Institute DSMZ-German 
Collection of Microorganisms and Cell Cultures. 
Human tissue for isolation of primary human hepatocytes 
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Double-coded tissues and corresponding data used in this study were provided 
by the Biobank of the Department of General, Visceral and Transplantation 
Surgery, Ludwig Maximilian University (LMU), Munich, Germany, under the 
administration of the Human Tissue and Cell Research (HTCR) Foundation. The 
framework of HTCR Foundation 61, which includes obtaining written informed 
consent from all donors, has been approved by the ethics commission of the 
Faculty of Medicine at the LMU (approval number 025-12) as well as the 
Bavarian State Medical Association (approval number 11142), Germany. 
Primary human hepatocytes were isolated by the Cell Isolation Core Facility of 
the Biobank using a two-step collagenase perfusion technique with 
modifications, as described earlier 62. 
Western blot  
Equal amount of proteins in each sample was loaded on 10% or 12% SDS-
PAGE gels and separated for 25 minutes at 80 V and for 80 minutes at 120 V, 
then transferred onto PVDF membranes (EMD Millipore Corporation, USA). 
After blocking for 1 hour in TBST (Tris-Buffered Saline with Tween-20) 
containing 5% milk or 5% bovine serum albumin (Carl Roth, Germany), 
membranes were incubated overnight at 4°C with the following primary 
antibodies: OLFM4, MMP-2 (Cell Signaling Technology, USA), MMP-7, 
MMP-9 (Cell Signaling Technology, USA), E-cadherin, and β-actin (Cell 
Signaling Technology, USA). Subsequently the membranes were probed with 
horseradish-peroxidase conjugated secondary anti-rabbit or -mouse IgG 
antibodies (GE Healthcare, UK Limited) for 2 hours at room temperature at the 
dilution of 1:10,000. The bands were visualized by SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, Germany) and photographed 
with an image acquisition system, ECL ChemoCam Imager (Intas GmbH, 
Germany). 
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siRNA interference  
Cells were plated to reach a confluence of 40% to 60%. After overnight 
incubation, cells were transfected using Oligofectamine (Invitrogen, Germany) 
and siRNA directed against OLFM4 (siRNA-1, sense: 
GAGUUAACCUGACCACCAATT, antisense: 
UUGGUGGUCAGGUUAACUCTG. siRNA-2, sense: 
GGGAUUCUUUGUACAGGAATT, antisense: 
UUCCUGUACAAAGAAUCCCTA. Qiagen, Germany) or with beta-
galactosidase (Dharmacon Inc., USA), which served as control at a final 
concentration of 50 nM. Serum-containing medium was added 4 hours after 
transfection. Silencing of OLFM4 was confirmed by immunoblotting 24 hours 
after transfection. 
Immunofluorescence  
75,000 cells/well were plated on round cover slips (Thermo Scientific, 
Germany) with a diameter of 18 mm in 6-well plates (NUNC, Germany). After 
24 hours after transfection with siRNA cells were fixed in paraformaldehyde 
(4%, Carl Roth, Germany) for 15 minutes, treated with 0.15% Triton X-100 
(Sigma-Aldrich, Germany) for 15 minutes in PBS (Invitrogen, Germany), then 
blocked for 30 minutes with 5% BSA in PBS. Samples were incubated with 
antibodies against OLFM4 and E-cadherin diluted in blocking solution at 1:200 
at 4°C overnight and after washing, subsequently incubated for 1 hour with goat 
anti-rabbit antibody conjugated with Alexa Fluor 488 (Invitrogen, Germany) at 
1:200 dilution. After three washes with PBS, slides were mounted with 
Vectashield (Vector Laboratories Inc., USA) containing Hoechst 33342 (Sigma-
Aldrich, Germany). Pictures were taken using the Axiovert 135 TV fluorescence 
microscope (Zeiss, Germany). 
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Flow cytometry  
Sub-G1 events and cell cycle distribution were assessed to measure apoptosis 
and different phases of cell cycle by using fluorescence-activated cell sorter 
(FACS), Accuri C6 Flow Cytometer and BD Accuri C6 software (BD 
Biosciences, Germany). Cells were seeded in 6-well plates to reach a confluence 
of 50% to 60% before undergoing transfection with siRNA. After 24 hours, the 
cells were split by trypsin (Invitrogen, Germany), collected and washed with 
sterilized, ice-cold PBS once, then incubated in staining buffer containing 0.1% 
sodium citrate (Carl Roth, Germany), 0.1% Triton X-100 and 50 µg/ml 
propidium iodide (PI; Sigma-Aldrich, Germany).  
Proliferation assay 
1,000 to 1,500 cells were seeded in 96-well plates (NUNC, Germany) cultured 
overnight and then incubated with siRNA. After 6 days, cells were washed with 
PBS and underwent osmotic lysis in 100 µl ddH2O for 45 minutes at 37°C. 0.2% 
Sybr green (Lonza, USA) was added to each well, fluorescence was measured 
and proliferation index was calculated as a ratio to untreated samples. Three 
independent experiments were performed per agent, with each data point 
reflecting triplicate wells. Error bars represent standard deviation (SD) of the 
mean from three experiments.  
Scratch assay  
Cells were seeded in 6-well plates to reach a confluence of 80% and treated as 
indicated in the siRNA section. After cells became confluent, a scratch was 
made through by a sterile micropipette tip (Sarstedt AG & Co., Germany). The 
scratch-area was photographed after the scratch was performed and after 24 
hours to assess cell migration within the wounded area. Migration was 
quantified by measuring the area of the scratched regions by ImageJ software 
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(National Institutes of Health, Bethesda, Maryland, USA, 
https://imagej.nih.gov/ij/). The experiment was performed three times. 
Migration and invasion assay  
The chamber of 8-μm transwell inserts (Corning, USA) with or without Matrigel 
(Corning, USA) was used for migration and invasion assay. 2 x 105 cells 
underwent incubation in the serum-free top chamber while serum-containing 
medium was added to the lower chamber. To assess the fraction of cells which 
migrated, staining with 1% crystal violet (Sigma-Aldrich, Germany) was 
performed after 24 hours of incubation and fixation in 10% formalin (Carl Roth, 
Germany). For microscopy cells were evaluated at a magnification of × 200 
(Zeiss, Germany). 
Cancer genome atlas analyses  
Publically available RNA sequencing data of HCC samples (N = 423) were 
downloaded from The Cancer Genome Atlas (TCGA) (http:// 
cancergenome.nih.gov/). The analyses of fragments per kilobase of transcript 
per million fragments (FPKM) values of genes in TCGA HCC patient samples 
and survival outcome were conducted as previously described 63.  
Statistical analysis 
All statistical analyses were calculated using SPSS (version 24; SPSS, Inc.). For 
frequency data, exact χ2 tests were used. Differences between groups were 
calculated by the Student’s t-test. Overall survival was estimated with the 
Kaplan-Meier method and tested with the log-rank procedure. For analysis of 
survival a Cox proportional hazards regression model was used and reported by 
hazard ratios (HR) and 95% confidence intervals (CI). Statistical significance 
was set for a P value < 0.05.
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RESULTS 
Patients and clinicopathological parameters.  
157 HCC patients included in the constructed TMA from surgical specimens of 
patients undergoing liver resection or liver transplantation were considered for 
clinicopathological analysis. To avoid biases related to the effect of 
transplantation on patients’ outcome, 56 patients who had undergone liver 
transplantation were not considered for survival analysis, which was performed 
in 95 out of 101 patients with available survival data. The demographic and 
clinicopathologic characteristics of the patients in our cohort are presented in 
Table 1. For patients included in the survival analysis, the median follow-up 
time was 22 months. The median follow-up for survivors was 42 months vs. 17 
months for deceased patients.  
 
Immunohistochemical staining for OLFM4 in HCC cells and in hepatocytes 
from surrounding non-tumour tissues.  
In non-tumour tissues, OLFM4 stained positive in altogether 68.5% showing a 
pattern of mixed membrane and cytoplasmatic staining in 39.5% of patients, of 
cytoplasmatic staining only in 27.3% of patients, and a membrane-only staining 
in 1.7% of samples. No staining for OLFM4 could be detected in 31.5% of 
samples from non-tumor tissues. In HCC samples, altogether 87.6% showed a 
positive staining for OLFM4: cytoplasmatic staining for OLFM4 (26% of 
samples) was similar to that observed in non-tumor tissues, whilst the fraction of 
patients with staining on both membranes and cytoplasm increased to 61.6% 
(Fig. 1A, B). Altogether, OLFM4 staining in cell cytoplasm was more common 
than in matched, surrounding HCC lesions (OLFM4: 66.8% in normal cells 
versus 87.6% in HCC; Pearson’s χ2 test: P < 0.001). This difference was 
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principally due to the higher fraction of HCC samples showing a pattern of 
mixed cytoplasmatic and membrane staining for OLFM4 (61.6% of tumor 
samples versus 41.2% of nontumor samples exhibited positive membrane 
staining for OLFM4; Pearson’s χ2 test: P < 0.001).  
 
Correlations between OLFM4 staining and clinical and pathological 
characteristics of tumour tissues and non-tumour tissue samples.  
We next assessed the correlation between OLFM4 staining in both tumour and 
non-tumor specimens and the available demographic and clinicopathologic 
features of the collective, including etiology of underlying liver disease, age and 
gender of patients, presence of liver cirrhosis, grading and size of tumors and the 
presence of vascular invasion. In addition, established immunohistochemical 
markers related to cell invasion and aggressive phenotype in HCC, including 
expression of E-cadherin 64 and MMP-7 were included in the analysis (Table 2).  
Positive cytoplasmatic staining for OLFM4 in tumour samples was associated to 
the presence of lobular inflammation in the surrounding non-tumour tissue (P < 
0.001), MMP-7 expression (P = 0.002) and blood vessel invasion (P = 0.048). 
Furthermore, significant association was observed between the membrane 
staining for OLFM4 and the expression of E-cadherin (P = 0.042) and MMP-7 
(P = 0.015) in tumor samples. In contrast, no relevant correlation were found 
between clinicopathologic variables and OLFM4 staining in matched non-
tumour tissues samples (data not shown). 
 
Prognostic significance of OLFM4 staining in patients undergoing liver 
resection.  
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Since the higher prevalence of OLFM4 staining in tumor samples suggested a 
role of this molecule in tumor development, a survival analysis was performed 
to assess the prognostic significance of OLFM4 in patients undergoing partial 
hepatectomy (Fig. 2A). A Kaplan-Meier analysis revealed the presence of 
vascular invasion (Fig. 2B; P = 0.002) and cytoplasmatic staining of OLFM4 
(Fig. 2C; P = 0.008) as predictors of survival. Specifically, patients showing 
OLFM4 staining in the cell cytoplasm had a poorer outcome compared to 
patients without cytoplasmatic staining for OLFM4 (5-year overall survival: 
58.3% versus 17.3%, respectively). This was corroborated by a survival analysis 
performed according to semiquantitative criteria defining OLFM4 cytoplasm 
staining intensity (negative, weak and strong - Fig. 2D; 5-years overall survival 
were 70.7%, 21.6%, and 15.7%, respectively, P = 0.005). In contrast, membrane 
staining did not affect survival (Fig. 2E; P = 0.154, Fig. 2F; P = 0.123). In 
addition, survival analyses based on presence or absence of OLFM4 staining, 
regardless of cellular distribution or intensity, was not associated with patients’ 
outcome, suggesting that in addition to higher expression, cellular distribution 
plays a role in determining the functional effect of OLFM4 during tumor 
development (Fig. 2G, P = 0.147; 2H, P = 0.166). This was confirmed by 
assessment of mRNA expression in an independent cohort of HCC patients 
obtained from the publically available database of the TCGA showing that, 
survival of patients exhibiting high OLFM4 expression was numerically higher, 
but not statistically different, than in patients with low mRNA expression (Fig. 
3A, P = 0.0604).  
In addition, mRNA expression analysis confirmed the correlation observed at 
immunohistochemical level between OLFM4 expression and E-cadherin (Fig. 
3B, r = -0.102, P = 0.036) and MMP-7 (Fig. 3C, r = 0.456, P < 0.0001) in 
TCGA HCC cohorts, thus corroborating the finding that OLFM4 might 
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contribute to worse prognosis by impinging on these two regulator of cell 
motility and invasion. 
Cox univariate analyses taking into account age, gender, etiology, the existence 
of cirrhosis and steatosis, liver inflammation, necrosis, grading, tumor size, the 
presence of metastasis and multifocal lesions, the expression of E-cadherin and 
MMP-7, or signs of blood vessel invasion showed that the cytoplasm staining of 
OLFM4 (HR: 2.226; 95% CI: 1.186 – 4.177; P = 0.013) and vessel invasion 
(HR: 1.879; 95% CI: 1.181 – 2.989; P = 0.008) independently influence the 
survival of HCC patients after partial hepatectomy (Table 3). Cox multivariate 
analyses calculated HRs for OLFM4 cytoplasm staining was 2.135 (95% CI: 
1.135 – 4.015; P = 0.019) and for vessel invasion was 1.791 (95% CI: 1.124 – 
2.854; P = 0.014; Table 4). In contrast, no correlation was found between 
OLFM4 staining in non-tumour surrounding tissues and survival of patients 
(data not shown). 
 
OLFM4 silencing suppresses cell migration and invasion, and causes cell 
cycle arrest in vitro.  
To assess the functional relevance of OLFM4, and validate in vitro the observed 
association between this protein and MMP-7, or E-cadherin observed in 
immunohistochemical studies, we assessed the effect of silencing of OLFM4 by 
siRNA and its basal expression in HCC cancer cells and in primary human 
hepatocytes (Fig. 4A, C). As shown in Fig. 4B, the effect of siRNA-silencing on 
OLFM4 was observable within 24 hours. As expected, OLFM4 knockdown 
inhibited the expression of MMP-7, -2, and -9, and increased the expression of 
E-cadherin levels. Consistently, both cytoplasm and membrane expression of 
OLFM4 were diminished after siRNA-silencing incubation as shown by 
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immunofluorescence in HCC cell lines (Fig. 4D). As alterations of E-cadherin 
and MMP-family molecules are involved in the process of cell invasion and the 
development of metastasis 65-67, we performed scratch- and transwell-assays to 
determine the effect of OLFM4 silencing on cell invasion and metastasis in 
vitro. To this regard, we observed that cell motility was greatly diminished in 
OLFM4-siRNA transfected cells vs. control cells as judged both by the 
assessment of healing areas at the scratch assay (Fig. 5A-C) and by decreased 
cell migration in transwell chambers (Fig. 5D-H). These results indicate that 
OLFM4 impinges on cell motility and invasive properties and represent a 
correlate for the immunohistochemical and prognostic data. 
Finally, as OLFM4 was previously reported to affect apoptosis 68,69, we here 
investigated whether OLFM4, besides affecting cell motility, also affects cell 
viability and proliferation. As shown by the significant increase of sub-G1 
events after PI-staining, we found a small but significant increase of apoptosis 
after siRNA-OLFM4 incubation for 24 hours (Fig. 5I, J). In addition, a G1 cell 
cycle arrests was observed, along with a corresponding decrease of the S and 
G2/M phases of cell cycle (Fig. 5I, J). 
Taken together, these results indicate that OLFM4 down-regulation affects the 
viability of HCC cells mainly by activating apoptosis and inducing G1 cycle 
arrest. The corresponding expressive variation of MMP family and E-cadherin 
reveals the important role of OLFM4 in HCC adhesion and metastasis.
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DISCUSSION 
Staining, localization and prognostic significance of OLFM4 in tumours 
versus surrounding non-tumour tissues. 
OLFM4, also known as GW112 or G-CSF-stimulated clone 1 protein (hGC-1), 
is a glycoprotein with a molecular weight of 64 kDa originally cloned from 
human myeloblasts 70. OLFM4 is known to play multiple roles as a mediator of 
inflammation and cellular differentiation 41,71. However, evidence has 
accumulated on the fact that OLFM4 plays a role in the development of different 
tumor entities and might contribute to determine chemoresistance 50,52,72. To the 
best of our knowledge, no systematic study has been conducted to assess the 
prognostic relevance of the OLFM4 family in HCC. 
In agreement with the notion that OLFM4 expression plays a role in cancer 
formation, we found that 87.6% of cancer samples, but only 68.5% of matched 
non-tumour samples exhibited a positive staining of OLFM4 (Fig. 1). This is in 
accordance with previous findings showing that OLFM4 was significantly 
higher in serum of patients with solid tumours such as gastric, colorectal, 
pancreatic, head and neck, or prostate cancers than in healthy individuals 55. 
Interestingly, however, as we assessed the prognostic significance of OLFM4, 
no association between survival and overall staining or semiquantitative staining 
intensity of OLFM4 at immunohistochemistry or by stratifying patients by 
mRNA expression levels could be found. As we categorized our samples 
according to the fraction of tumours exhibiting OLFM4 staining on cell 
membrane vs. samples with cytoplasmatic staining, we observed that tumor and 
non-tumor samples essentially differed in the proportion of specimens with a 
cytoplasmatic staining (Fig. 1). Correspondingly, as we assessed the relevance 
of OLFM4-expression on survival in HCC patients, five-year survival of 
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patients with tumours exhibiting OLFM4 staining in cell cytoplasm showed a 
poorer prognosis in comparison to patients without OLFM4 staining (Fig. 2C, 
E; Table 3, 4). 
Previous immunohistochemical studies have reported that OLFM4 can be 
localized in virtually all cell compartments including the mitochondria 46,54, and 
the cell nucleus 54. In addition, OLFM4 is known to be secreted 73 outside the 
cell and to be detectable in plasma of patients. The cytoplasmatic localization 
observed in our samples likely represents the functional correlate of OLFM4 
with histological type and differentiation of HCC. 
 
Clinical-pathologic correlations of OLFM4 staining and functional 
assessment of OLFM4 in vitro. 
To assess the role of OLFM4 in the pathogenesis of HCC, we attempted at 
finding a correlation between OLFM4 staining and pathological features 
defining the severity of the liver disease underlying the occurrence of HCC in 
the patients of our collective, and hypothesized that increasing severity of liver 
disease (e.g. increasing fibrosis, steatosis or lymphocyte infiltration) would be 
accompanied by increasing staining of OLFM4. To this regard, we observed that 
cytoplasm staining for OLFM4 in tumour samples was associated with lobular 
inflammation of liver (P < 0.001), which possibly reflects an unfavorable effect 
of OLFM4 on tumor inflammation (Table 2) 74. Furthermore, as we assessed the 
correlation between OLFM4 and tumor-specific clinical-pathological 
characteristics, we found a correlation between staining for OLFM4 and blood 
vessel invasion (P = 0.048), staining for MMP-7 (P = 0.002) and of E-cadherin 
status (P = 0.042; Table 2). This was confirmed by the analysis of the 
correlation between OLFM4, E-cadherin and MMP-7 mRNA expression 
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observed in the second independent cohort, and by in vitro experiments, which 
confirmed the causal relationship between expression of OLFM4 and that of E-
cadherin and MMP-7. In addition, these in vitro experiments confirmed the 
functional role of OLFM-4 in determining cell viability and metastatic 
properties of cancer cells. Collectively, our findings show that OLFM4 may play 
a role in regulating tumour invasiveness in HCC cells by activating MMP-7 
expression, which causes degrading of the basal membrane and inhibits E-
cadherin expression (Fig. 6), thus contributing to the malignant phenotype of 
HCC. 
 
Possible clinical consequences of OLFM4 expression in liver cancer cells. 
Although the mechanism, by which OLFM4 overexpression causes the reported 
bad prognostic effects in tumour cells, our results are in keep with that of several 
other studies which provided evidence that increased OLFM4 expression is 
associated with an aggressive tumor phenotype 42-45,47. The multivariate analysis 
of our data, comprising the determination of tumor stage at diagnosis and other 
important characteristics like vascular invasion, define OLFM4 as a prognostic 
marker for HCC, suggesting that OLFM4 could be investigated prospectively as 
marker of aggressiveness and, as previously suggested 41,55, as a marker of 
response to treatment. To this regard, future studies will have to address the 
issue of the role played by OLFM4 within well-established, potentially 
actionable signalling pathways, such as the PI3K-Akt-Tor signalling, beta-
catenin, RAS-RAF-MEK-ERK, PDGF, and MET signalling. In addition, serum 
OLFM4 levels have been proposed as a biomarker for gastric and colorectal 
cancer with the potential of identifying patients at risk of recurrence or 
progression 50,52,75. Whether this could be translated to the case of HCC – thus 
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providing a circulating marker of aggressiveness and possibly of response to 
treatment, will be the interesting object of future studies. 
 
Summary 
Increased expression of OLFM4 is a common event in the pathogenesis of HCC. 
These findings warrant further investigation of the role of this molecule in 
mediating development of HCC and in particular its role in determining the 
metastatic properties of cancer cells.
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Fig. 1. Expression and cellular distribution of OLFM4 in tumor and non-tumor tissue 
samples. A. B. Staining of OLFM4 in HCC cells and in non-tumor cells: proportion of 
samples showing no staining (none), cytoplasmatic staining (cytoplasm only), membrane 
staining (membrane only), or both (m+c). Representative cytoplasm staining pattern in HCC 
samples: (C) score 0, negative; (D) score 1, weak; (E) score 2, strong. Representative typical 
positive membrane and cytoplasm staining in HCC tissues: (F) score 0, negative; (G) score 1, 
less than 30% of cells; (H) 30% - 70% of cells; (I) over 70% of cells. Magnification, x 40. 
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Fig. 2. Prognostic significance of OLFM4 according to cellular distribution. A. Overall 
survival (OS) of the entire patients’ collective as determined by the Kaplan-Meier method. B. 
OS according to evidence of vessel invasion. OS according to cytoplasm staining for OLFM4 
(positive or negative (C)) or according to semiquantitative assessment of staining intensity 
(D). OS according to membrane staining for OLFM4 (positive or negative (E)) or according 
to semiquantitative assessment of staining intensity (F). G. Overall survival (OS) according to 
OLFM4 staining in HCC tissues and in non-HCC tissue samples (H). +: Censored cases. 
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Fig. 3. Prognostic significance of OLFM4 and correlation with E-Cadherin or MMP-7 
according to mRNA expression analysis of an independent cohort. A-C, expression of 
OLFM4 mRNA in a second independent cohort of HCC patients. (A) Kaplan-Meier survival 
curves according to mRNA expression levels. Assessment of the correlations between 
OLFM4 and E-cadherin (B) or MMP-7 (C) mRNA expression levels from the same patients’ 
collective.  
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Fig. 4. In vitro assessment of the effect of OLFM4 silencing on MMP-7 and E-cadherin. 
A. Baseline levels of OLFM4, MMP-7, and E-cadherin expression in Huh7 and PLCPRF5 
cell lines. B. Effect of transfection of Huh7 and PLCPRF5 cells with siRNA specifically 
targeting OLFM4 or non-coding siRNA (Beta-gal, 50 nM) for 24 hours on the expression of 
the indicated molecules after immunoblotting. C. Basal expression of OLFM4 in primary 
OLFM4 FIGURES 
 
 
67 
 
 
non-tumor hepatocytes isolated from three patients. D. Typical pattern of OLFM4 expression 
at immunofluorescence after transfection with control- or OLFM4-targeting siRNA.  
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Fig. 5. Effect of OLFM4 silencing on cell migration and invasion. A. B. Assessment of cell 
motility by wound healing assay in Huh7 or PLCPRF5 cells transfected with siRNA-OLFM4 
or control-si-RNA. C. Quantitative analysis of healing area in percentages. D. E. The 
migration and invasion of Huh7 and PLCPRF5 cells transfected with siRNA-OLFM4 
compared with the controls by transwell assay after 24 hours. F. G. Quantitative analysis of 
migration and invasion cells. H. The E-cadherin expression of Huh7 and PLCPRF5 cells 
transfected with siRNA-OLFM4 compared with the controls by immunofluorescence after 24 
hours. I-J: Effects of OLFM4-silencing by siRNA on sub-G1 events, cell cycle distribution, 
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and cell viability in Huh7 (I) and PLCPRF5 (J) cell lines. Values represented mean ± SD 
from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test. 
 
Fig. 6. Schematic diagram describing the hypothesized effect of OLFM4, MMP family 
members and on invasion and metastasis formation in HCC.
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TABLES 
Table 1. Summary of clinical and pathologic features. 
Feature 
Patient count 
N % 
Age at diagnosis (y)   
< 60 70 44.6 
≥ 60 87 55.4 
Sex   
Male 122 77.7 
Female 35 22.3 
Etiology   
HCV 42 26.8 
HBV 16 10.1 
Toxic/metabolic 92 58.6 
Unknown 7 4.5 
Severe fibrosis/cirrhosis   
< 5 64 40.8 
≥ 5 88 56.0 
Not available 5 3.2 
Steatosis   
0 65 41.4 
1 - 3 87 55.4 
Not available 5 3.2 
Portal inflammation   
0 - 2 71 45.2 
3 - 4 81 51.6 
Not available 5 3.2 
Piecemeal necrosis   
0 - 2 119 75.8 
3 - 4 33 21.0 
Not available 5 3.2 
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Lobular inflammation   
0 - 1 113 72 
2 - 3 39 24.8 
Not available 5 3.2 
Tumor size (cm)   
< 5 81 51.6 
≥ 5 76 48.4 
Extrahepatic metastasis   
No 151 96.2 
Yes 6 3.8 
Grading    
1 29 18.5 
2 81 51.6 
3 33 21.0 
Not available 14 8.9 
Blood vessel invasion   
No 122 77.1 
Yes 35 22.9 
Multifocal lesions   
No 106 67.5 
Yes 47 29.9 
Not available 4 2.5 
E-cadherin   
0 - 1 21 13.4 
2 - 3 132 84.1 
Not available 4 2.5 
MMP-7   
0 - 1 27 17.2 
2 - 3 129 82.2 
Not available 1 0.6 
Treatment   
Liver transplantation 56 35.7 
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Partial hepatectomy 101 64.3 
 
Table 2. Correlation between OLFM4 staining and 
clinicopathologic parameters in HCC cells. 
Feature 
Cytoplasm staining 
P 
Negative, N (%) Positive, N (%) 
Age at diagnosis (y)    
< 60 11 (7.0) 59 (37.6) 
0.316 
≥ 60 9 (5.7) 78 (49.7) 
Sex    
Male 13 (8.3) 109 (69.4) 
0.144 
Female 7 (4.5) 28 (17.8) 
Etiology    
HCV 4 (2.7) 38 (25.3) 
0.684 HBV 2 (1.4) 14 (9.3) 
Toxic/metabolic 14 (9.3) 78 (52.0) 
Severe fibrosis/cirrhosis    
< 5 11 (7.2) 53 (34.9) 
0.232 
≥ 5 9 (5.9) 79 (52.0) 
Steatosis    
0 13 (8.6) 52 (34.2) 
0.05 
1 - 3 7 (4.6) 80 (52.6) 
Portal inflammation    
0 - 2 8 (5.6) 63 (41.4) 
0.633 
3 - 4 12 (7.9) 69 (45.4) 
Piecemeal necrosis    
0 - 2 16 (10.5) 103 (67.8) 
0.842 
3 - 4 4 (2.6) 29 (19.1) 
Lobular inflammation    
0 - 1 7 (4.6) 106 (69.7) 
< 0.001* 
2 - 3 13 (8.6) 26 (17.1) 
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Tumor size (cm)    
< 5 10 (6.4) 71 (45.2) 
0.879 
≥ 5 10 (6.4) 66 (42.0) 
Extrahepatic metastasis    
No 18 (11.5) 133 (84.7) 
0.169¶ 
Yes 2 (1.3) 4 (2.5) 
Grading     
G1 2 (1.4) 27 (18.9) 
0.367¶ 
G2 and G3 18 (12.6) 96 (67.1) 
Blood vessel invasion    
No 19 (12.1) 103 (65.6) 
0.048*¶ 
Yes 1 (0.6) 34 (21.7) 
Multifocal lesions    
No 15 (9.8) 91 (59.5) 
0.552 
Yes 5 (3.2) 42 (27.5) 
E-cadherin    
0 - 1 3 (1.9) 18 (11.8) 
0.74 
2 - 3 17 (11.1) 115 (75.2) 
MMP-7    
0 - 1 9 (5.8) 18 (11.5) 
0.002*¶ 
2 - 3 11 (7.1) 118 (75.6) 
 
 
Feature 
Membrane staining 
P 
Negative, N (%) Positive, N (%) 
Age at diagnosis (y)    
< 60 28 (17.8) 42 (26.8) 
0.680 
≥ 60 32 (20.4) 55 (35.0) 
Sex    
Male 45 (28.7) 77 (49.0) 
0.522 
Female 15 (9.6) 20 (12.7) 
Etiology    
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HCV 21 (14.0) 21 (14.0) 
0.236 HBV 7 (4.7) 9 (6.0) 
Toxic/metabolic 32 (21.3) 60 (40.0) 
Severe fibrosis/cirrhosis    
< 5 27 (17.8) 37 (24.3) 
0.559 
≥ 5 33 (21.7) 55 (36.2) 
Steatosis    
0 31 (20.4) 34 (22.4) 
0.052 
1 - 3 28 (18.4) 59 (38.8) 
Portal inflammation    
0 - 2 22 (14.5) 49 (32.2) 
0.088 
3 - 4 36 (23.7) 45 (29.6) 
Piecemeal necrosis    
0 - 2 48 (31.6) 71 (46.7) 
0.456 
3 - 4 11 (7.2) 22 (14.5) 
Lobular inflammation    
0 - 1 43 (28.3) 70 (46.1) 
0.811 
2 - 3 14 (9.2) 25 (16.4) 
Tumor size (cm)    
< 5 34 (21.7) 47 (29.9) 
0.317 
≥ 5 26 (16.6) 50 (31.8) 
Extrahepatic metastasis    
No 59 (37.6) 92 (58.6) 
0.408¶ 
Yes 1 (0.6) 5 (3.2) 
Grading     
G1 13 (9.2) 16 (11.1) 
0.289 
G2 and G3 39 (27.3) 75 (52.4) 
Blood vessel invasion    
No 45 (28.7) 77 (49.0) 
0.522 
Yes 15 (9.6) 20 (12.7) 
Multifocal lesions    
No 42 (27.5) 64 (41.8) 0.686 
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Yes 17 (11.1) 30 (19.6) 
E-cadherin    
0 - 1 12 (7.8) 9 (5.9) 
0.042* 
2 - 3 45 (29.4) 87 (56.9) 
MMP-7    
0 - 1 16 (10.3) 11 (7.0) 
0.015* 
2 - 3 44 (28.2) 85 (54.5) 
 
*, statistical significance; ¶, Fisher’s exact test. All other P values were calculated by 
Pearson’s Chi-square test. 
 
Table 3. Cox regression of univariate analyses for  
OLFM4 staining in HCC tissues. 
Parameter HR 95% CI P 
Age at diagnosis (y)    
< 60    
≥ 60 0.946 0.624 - 1.434 0.795 
Sex    
Male    
Female 1.084 0.669 - 1.755 0.743 
Etiology    
HCV    
HBV 1.001 0.459 - 2.183 0.998 
Toxic/metabolic 1.085 0.659 - 1.787 0.747 
Severe fibrosis/cirrhosis    
< 5    
≥ 5 1.286 0.844 - 1.958 0.242 
Steatosis    
0    
1 - 3 0.725 0.473 - 1.111 0.140 
Portal inflammation    
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0 - 2    
3 - 4 1.202 0.787 - 1.835 0.395 
Piecemeal necrosis    
0 - 2    
3 - 4 1.580 0.966 - 2.584 0.068 
Lobular inflammation    
0 - 1    
2 - 3 0.702 0.434 - 1.133 0.148 
Tumor size (cm)    
< 5    
≥ 5 0.950 0.617 - 1.462 0.815 
Extrahepatic metastasis    
No    
Yes 1.186 0.432 - 3.251 0.741 
Grading     
1    
2 0.719 0.424 - 1.219 0.220 
3 1.179 0.658 - 2.112 0.580 
Blood vessel invasion    
No    
Yes 1.879 1.181 - 2.989 0.008* 
Multifocal lesions    
No    
Yes 1.150 0.727 - 1.820 0.549 
E-cadherin    
0 - 1    
2 - 3 0.623 0.342 - 1.137 0.123 
MMP-7    
0 - 1    
2 - 3 1.028 0.590 - 1.790 0.923 
Cytoplasm staining    
Negative    
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Positive 2.226 1.186 - 4.177 0.013* 
Membrane staining    
Negative    
Positive 1.216 0.781 - 1.891 0.386 
*, statistical significance. HR, hazard ration. CI, confidence interval. 
 
Table 4. Cox regression of multivariate analyses for  
OLFM4 staining in HCC tissues. 
Parameter HR 95% CI P 
Blood vessel invasion    
No    
Yes 1.791 1.124 - 2.854 0.014* 
Cytoplasm staining    
Negative    
Positive 2.135 1.135 - 4.015 0.019* 
*, statistical significance. HR, hazard ration. CI, confidence interval.
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TBS/T      Tris buffered saline with Tween 
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